These results suggest that the inhibition of hepatic lipid accumulation and BA stasis using the LGZG oral solution, which exerts therapeutic effects on MASLD, may be associated with the microbiota–BA–FXR/TGR5 axis. Here, GPBAR1 is linked to metabolic dysfunction-associated steatotic liver disease.